Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04657926
Other study ID # APPA-P2-1
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date September 9, 2020
Est. completion date October 1, 2021

Study information

Verified date November 2021
Source AKL Research and Development
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A placebo controlled study of APPA in 150 participants with Osteoarthritis of the knee


Description:

This is a multicenter, randomized, double-blind, placebo-controlled, parallel group, 4-week trial of a fixed-dose combination of apocynin and paeonol (APPA) administered orally twice daily versus placebo twice daily. Approximately 150 subjects will be randomized to one of the two treatment groups.


Recruitment information / eligibility

Status Completed
Enrollment 152
Est. completion date October 1, 2021
Est. primary completion date September 30, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: 1. Subject is able to read and understand the language and content of the study material, understand the requirements for study visits, and is willing to provide information at the scheduled evaluations and appropriate written informed consent has been obtained. 2. Femorotibial osteoarthritis of the knee, according the American College of Rheumatology (ACR) clinical and radiographic criteria (Altman et al., 1986) (Appendix A). 3. Radiological OA grade 2 or 3 of the target knee, using the Kellgren-Lawrence method (Kellgren and Lawrence, 1957) as graded by central, independent reading of X-ray obtained during screening, or on a recent (within 6 months) X-ray image which fulfills the protocol specifications for reading. 4. Age between 40 years and 85 years at the time of screening, both included; of either sex. 5. Pain score rated on an 11-point numerical rating scale of the target knee of = 20 and = 45 out of 50 in response to the WOMAC pain sub-score (5 questions), at the time of screening and baseline. The subject should have undergone a washout-period of at least 5 half-lives of any analgesic medication before completing the screening and baseline questionnaires. 6. Women of child-bearing potential must use a highly effective method of contraception(please see Appendix B). Postmenopausal status is defined as being amenorrheic for at least 1 year prior to screening. Sexually active men with a female partner of childbearing potential must ensure that their female partner uses a highly effective method of contraception and agree to use condom from enrolment up to at least 3 months after the study end. Furthermore, male participants must agree not to donate sperm throughout the study and at least 3 months after he study end. 7. Knee pain in the target knee for 14 days of the preceding month (periarticular knee pain due to OA and not due to non-OA conditions such as bursitis, tendonitis, etc.) based on subject report. 8. Inadequate response to or intolerance to analgesics and/or non-steroidal anti-inflammatory drugs (NSAIDs) as reported by the subject Exclusion Criteria: 1. Known or suspected hypersensitivity to or previous hypersensitivity reactions to APPA, or any of the excipients in the investigational product. 2. For women of childbearing potential: 1. Pregnancy (i.e. positive pregnancy test at Screening) or breastfeeding 2. Failure to agree to practice a highly effective method of contraception (see Appendix B), from enrolment up to at least 3 months after the study end. 3. For sexually active men with a female partner of childbearing potential: Failure to agree to ensure that their female partner uses a highly effective method of contraception, to agree to use condom (see Appendix B) from enrolment up to at least 3 months after the study end, and to agree not to donate sperm throughout the study and at least 3 months after the study end. 4. Intra-articular delivery of corticosteroids within 3 months or hyaluronic acid within 6 months of screening in the target knee or into any other joint within 30 days of screening. 5. Systemic corticosteroid treatment of more than 14 days during the past 6 months prior to screening. 6. Major surgery or arthroscopy of the target knee within the previous year prior to screening. 7. Planned surgery on either knee within the next 3 months. 8. Use of a currently unapproved investigational drug, device or biologic within 3 months prior to screening. 9. Presence of inflammatory arthritis, such as rheumatoid arthritis, psoriatic arthritis, polymyalgia rheumatica, gout or pseudogout with history of clinical attacks. 10. Current malignancy or treatment for malignancy within the past five years, with the exception of treated non-melanoma skin cancer, unless affecting the target knee area, or carcinoma in situ events. 11. Any other abnormal laboratory results or significant medical conditions that the Investigator believes should preclude the subject's participation in the trial. 12. Prior septic arthritis of the target knee. 13. Known osteoarthritis of the hip(s) if pain in either or both hip(s) exceeds that of the target knee using the WOMAC Hip Pain sub-score for that hip at the time of screening 14. Presence of significant radicular back pain, as reported by the subject. 15. Presence of severe pain in either knee, defined as > 45 out of 50 in response to the WOMAC pain sub-score (5 questions), at the time of screening or baseline, regardless of the eligibility of the contralateral knee. 16. Body Mass Index > 40.0 kg/m2. 17. Estimated glomerular filtration rate < 30 mL/min using the Modification of Diet in Renal Disease (MDRD) method. 18. Substantial use of moderate or higher strength opioid medication for the treatment of pain within 6 weeks before the screening visit, as evaluated by the investigator. 19. Use of duloxetine, pregabalin, or gabapentin within 4 weeks before the baseline visit. 20. History of alcohol or drug abuse within the past 5 years prior to randomization.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
APPA
APPA, an oral combination of two isomers: 4-hydroxy-3-methoxyacetophenone (4H3MA) & 2-hydroxy-4-methoxyacetophenone (2H4MA).
Placebo
Placebo capsules

Locations

Country Name City State
Denmark Sanos Clinic Copenhagen

Sponsors (2)

Lead Sponsor Collaborator
AKL Research and Development NBCD A/S

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Other Changes in serum and urine biomarkers of joint tissue turnover At baseline, and during the trial, serum and urine will be collected, for measurement of biomarkers reflecting collagen- and proteoglycan turnover 28 days
Other Time to achieve a clinically relevant pain reduction defined as a decrease from baseline of at least 1 points out of 10 in the 11-point average of daily pain score 28 days
Other Time to achieve "moderate improvement" and time to achieve "high improvement" in OMERACT-OARSI response 28 days
Primary WOMAC pain score change from baseline in WOMAC pain sub-score of the target knee as evaluated at week 4. 28 days
Secondary Changes from baseline in WOMAC total score and the WOMAC function and stiffness scores at week 4 28 days
Secondary Changes from baseline in constant, intermittent and total OA pain assessed by ICOAP scores at week 4 Changes from baseline in constant, intermittent and total OA pain assessed by ICOAP scores at week 4 28 days
Secondary Changes from baseline in WOMAC pain weight-bearing score (questions 1, 2, and 5) and non-weight bearing score (questions 3 and 4) at week 4 28 days
Secondary Changes from baseline in physical function assessed by the 20 Meter Walk Test gait speed at week 4 28 days
Secondary Change from baseline in the weekly mean of the average daily pain intensity at Week 4 28 days
Secondary Area-under-effect curves of the weekly mean of the average daily pain intensity at Week 4 28 days
Secondary OMERACT-OARSI responder rate at week 4 28 days
Secondary Total dose of rescue medication calculated as the sum of tablets used, based on pill counts 28 days
Secondary Time between baseline and first use of rescue medication 28 days
Secondary Changes from baseline in the Patient Global Assessment (PGA) score at week 4 28 days
Secondary Changes from baseline in quality of life assessed by the EQ5D at week 4 28 days
Secondary Safety Nature, incidence and severity of AEs. Changes in laboratory safety parameters, vital signs, 12-lead ECG parameters, and weight 28 days
See also
  Status Clinical Trial Phase
Completed NCT02536833 - A Study Evaluating the Safety, Tolerability, and Efficacy of SM04690 Injected in the Target Knee Joint of Moderately to Severely Symptomatic Osteoarthritis Subjects Phase 2
Completed NCT03014037 - Comparing Mesenchymal Stem Cell Counts in Unilateral vs. Bilateral Posterior Superior Iliac Spine Bone Marrow Aspiration N/A
Recruiting NCT05937542 - A Qualitative Investigation of CLEAT Participants
Completed NCT03644615 - A Mindfulness Program (MBSR) in the Management of Symptomatic Hip and Knee Osteoarthritis N/A
Recruiting NCT06061367 - Muscles Strength and Gait Parameteres After TKA
Withdrawn NCT04976972 - A Comparison of Patients Receiving a Total Knee Replacement With Robotic Assistance or With Conventional Instrumentation N/A
Completed NCT05496205 - A SAD Study to Evaluate the Safety, Tolerability and PK/PD of iN1011-N17 in Healthy Volunteers Phase 1
Completed NCT03850665 - Comparison of Functional Outcome in Patients After Hip Arthroplasty Depending on Surgical Approach N/A
Completed NCT02826902 - Effect of Anesthesia on Quality of Recovery in Patients Undergoing Correctional Tibial Osteotomy - A Randomized Controlled Trial N/A
Completed NCT04402502 - Dynamic 4DCT to Examine Wrist Carpal Mechanics N/A
Completed NCT02923700 - Leukocyte-rich PRP vs Leukocyte-poor PRP for the Treatment of Knee Cartilage Degeneration: a Randomized Controlled Trial Phase 4
Completed NCT04564053 - Study of Safety, Tolerability and Pharmacokinetics of LNA043 in Japanese Osteoarthritis Participants Phase 1
Completed NCT05070871 - A Clinical Trial Investigating the Effect of Salmon Bone Meal on Osteoarthritis Among Men and Women N/A
Not yet recruiting NCT05036174 - Diphenhydramine Ointment for Knee Osteoarthritis N/A
Recruiting NCT02912429 - Onlay vs. Inlay Patellofemoral Arthroplasty N/A
Recruiting NCT02666443 - Low Dose Dexamethasone in Supraclavicular Blocks N/A
Active, not recruiting NCT02723929 - Effects of tDCS and tUS on Pain Perception in OA of the Knee
Terminated NCT02820766 - Journey II BCS CMS Total Knee System Compared to Other PS Total Knee Systems in PT Setting N/A
Withdrawn NCT02921594 - Kinematic Comparison of Vanguard XP and Vanguard CR Total Knee Arthroplasties N/A
Completed NCT02544620 - Out Patient Surgery for Total Knee and Hip Replacement and Unicompartmental Knee Replacement - a Feasibility Study